Angiogenesis in malignant melanoma
Identifieur interne : 000F82 ( Main/Exploration ); précédent : 000F81; suivant : 000F83Angiogenesis in malignant melanoma
Auteurs : Moritz Felcht [Allemagne] ; Markus Thomas [Allemagne, Suisse]Source :
- JDDG: Journal der Deutschen Dermatologischen Gesellschaft [ 1610-0379 ] ; 2015-02.
Abstract
Despite the development of novel therapies, the therapy of malignant melanoma remains challenging. Various studies have shown the vascular system to be pivotal for metastasis in melanoma. Consequently, the effect of various antiangiogenic therapies has been and is being investigated in preclinical and clinical trials. While most studies focus on inhibition of vascular endothelial growth factor (VEGF) signaling, others are aimed at determining the effect of multikinase inhibitors or the inhibition of angiogenic integrin activity. However, overall survival rates have not significantly improved in clinical trials with antiangiogenic agents. Resistance to anti‐VEGF monotherapy has been observed in several studies, especially in malignant melanoma. Angiopoietin‐2 (Ang‐2) represents a promising candidate molecule for antiangiogenic therapy and the effect of Ang‐2 inhibitors is currently being explored in first trials. In melanoma, Ang‐2 has been shown to be a marker for metastasis formation and represents an interesting therapeutic target molecule. Future studies are required to analyze the effect of a combined approach, using anti‐VEGF and anti‐Ang‐2, as therapy for malignant melanoma.
Url:
DOI: 10.1111/ddg.12580
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002390
- to stream Istex, to step Curation: 002390
- to stream Istex, to step Checkpoint: 000127
- to stream Main, to step Merge: 000F83
- to stream Main, to step Curation: 000F82
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiogenesis in malignant melanoma</title><author><name sortKey="Felcht, Moritz" sort="Felcht, Moritz" uniqKey="Felcht M" first="Moritz" last="Felcht">Moritz Felcht</name></author><author><name sortKey="Thomas, Markus" sort="Thomas, Markus" uniqKey="Thomas M" first="Markus" last="Thomas">Markus Thomas</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:21FEFBE1481A9D069132EAAC38478C8EA75666FF</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/ddg.12580</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-C2T14G14-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002390</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002390</idno><idno type="wicri:Area/Istex/Curation">002390</idno><idno type="wicri:Area/Istex/Checkpoint">000127</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000127</idno><idno type="wicri:doubleKey">1610-0379:2015:Felcht M:angiogenesis:in:malignant</idno><idno type="wicri:Area/Main/Merge">000F83</idno><idno type="wicri:Area/Main/Curation">000F82</idno><idno type="wicri:Area/Main/Exploration">000F82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Angiogenesis in malignant melanoma</title><author><name sortKey="Felcht, Moritz" sort="Felcht, Moritz" uniqKey="Felcht M" first="Moritz" last="Felcht">Moritz Felcht</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Venereology, and Allergy, and Center of Excellence in Dermatology, the state of Baden‐Württemberg, Medical Faculty Mannheim at Heidelberg University, Mannheim</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Thomas, Markus" sort="Thomas, Markus" uniqKey="Thomas M" first="Markus" last="Thomas">Markus Thomas</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Roche Pharmaceutical Research and Early Development, Discovery Oncology, Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg</wicri:regionArea><wicri:noRegion>Penzberg</wicri:noRegion><wicri:noRegion>Penzberg</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Current address: Roche Pharmaceutical Research and Early Development, Discovery Ophthalmology, Roche Innovation Center Basel, F. Hoffmann‐La Roche, Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title><title level="j" type="alt">JDDG: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT</title><idno type="ISSN">1610-0379</idno><idno type="eISSN">1610-0387</idno><imprint><biblScope unit="vol">13</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="125">125</biblScope><biblScope unit="page" to="135">135</biblScope><biblScope unit="page-count">11</biblScope><date type="published" when="2015-02">2015-02</date></imprint><idno type="ISSN">1610-0379</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1610-0379</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Despite the development of novel therapies, the therapy of malignant melanoma remains challenging. Various studies have shown the vascular system to be pivotal for metastasis in melanoma. Consequently, the effect of various antiangiogenic therapies has been and is being investigated in preclinical and clinical trials. While most studies focus on inhibition of vascular endothelial growth factor (VEGF) signaling, others are aimed at determining the effect of multikinase inhibitors or the inhibition of angiogenic integrin activity. However, overall survival rates have not significantly improved in clinical trials with antiangiogenic agents. Resistance to anti‐VEGF monotherapy has been observed in several studies, especially in malignant melanoma. Angiopoietin‐2 (Ang‐2) represents a promising candidate molecule for antiangiogenic therapy and the effect of Ang‐2 inhibitors is currently being explored in first trials. In melanoma, Ang‐2 has been shown to be a marker for metastasis formation and represents an interesting therapeutic target molecule. Future studies are required to analyze the effect of a combined approach, using anti‐VEGF and anti‐Ang‐2, as therapy for malignant melanoma.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Suisse</li></country><region><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li></region><settlement><li>Mannheim</li></settlement></list><tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Felcht, Moritz" sort="Felcht, Moritz" uniqKey="Felcht M" first="Moritz" last="Felcht">Moritz Felcht</name></region><name sortKey="Felcht, Moritz" sort="Felcht, Moritz" uniqKey="Felcht M" first="Moritz" last="Felcht">Moritz Felcht</name><name sortKey="Thomas, Markus" sort="Thomas, Markus" uniqKey="Thomas M" first="Markus" last="Thomas">Markus Thomas</name></country><country name="Suisse"><noRegion><name sortKey="Thomas, Markus" sort="Thomas, Markus" uniqKey="Thomas M" first="Markus" last="Thomas">Markus Thomas</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:21FEFBE1481A9D069132EAAC38478C8EA75666FF
|texte= Angiogenesis in malignant melanoma
}}
| This area was generated with Dilib version V0.6.33. |  |